Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $41.83

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been assigned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $41.8333.

Several brokerages recently commented on STOK. Guggenheim began coverage on Stoke Therapeutics in a report on Thursday, February 5th. They set a “buy” rating and a $60.00 target price on the stock. Canaccord Genuity Group boosted their target price on Stoke Therapeutics from $36.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, March 20th. Wall Street Zen cut Stoke Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. BTIG Research reissued a “buy” rating and set a $39.00 target price on shares of Stoke Therapeutics in a report on Monday, May 11th. Finally, Wolfe Research began coverage on Stoke Therapeutics in a report on Monday, February 23rd. They set an “outperform” rating and a $40.00 target price on the stock.

Insider Buying and Selling

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 4,628 shares of the company’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $145,041.52. Following the transaction, the general counsel owned 28,836 shares of the company’s stock, valued at approximately $903,720.24. This represents a 13.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Adrian R. Krainer sold 33,243 shares of the company’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $39.74, for a total value of $1,321,076.82. Following the completion of the transaction, the director directly owned 283,302 shares in the company, valued at $11,258,421.48. This represents a 10.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 69,699 shares of company stock valued at $2,526,714 in the last three months. Insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. bought a new position in shares of Stoke Therapeutics in the third quarter valued at $1,062,000. Penserra Capital Management LLC bought a new position in shares of Stoke Therapeutics in the third quarter valued at $3,539,000. Vanguard Group Inc. raised its stake in Stoke Therapeutics by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock valued at $74,351,000 after purchasing an additional 217,616 shares during the period. Baillie Gifford & Co. acquired a new stake in Stoke Therapeutics during the 4th quarter valued at $7,837,000. Finally, Hussman Strategic Advisors Inc. acquired a new stake in Stoke Therapeutics during the 4th quarter valued at $2,000,000.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK opened at $29.34 on Thursday. Stoke Therapeutics has a 12 month low of $9.09 and a 12 month high of $40.22. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -10.44 and a beta of 1.20. The stock’s 50 day moving average price is $33.05 and its 200 day moving average price is $31.99.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Thursday, May 7th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.01. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%.The firm had revenue of $6.23 million for the quarter, compared to analysts’ expectations of $6.48 million. On average, sell-side analysts expect that Stoke Therapeutics will post -3.25 EPS for the current year.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.